Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,615.60
(
1.43%
)
Dow Jones
45,577.47
(
0.00%
)
Brent Oil
103.02
(
-4.73%
)
Bitcoin
69,866.06
(
2.97%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ciotera post# 171603

Friday, 12/20/2013 5:57:02 PM

Friday, December 20, 2013 5:57:02 PM

Post# of 257269
I’m glad you brought up Victrelis because it strengthens the case for ENTA, IMO. That a clearly second-rate drug could garner 25%+ of the Incivek + Victrelis market suggests that ABBV/ENTA ought to do considerably better than 25% in terms of volume share in all-oral GT1.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today